HOME
HIV-HCV Coinfection
Hepatitis C
HIV and AIDS
Hepatitis B
HIV-HBV Coinfection
HIV-HCV Coinfection
Profile of Patients Triply-infected with HIV, Hepatitis B and Hepatitis

Due to overlapping routes of transmission, some individuals are triply infected with HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV).

As reported in the May 31, 2008 issue of AIDS Research and Human Retroviruses, an international team of researchers studied a group of
HIV-HBV-HCV coinfected patients to characterize viral interactions in the HAART era.

All HIV infected patients with detectable anti-HCV antibodies and hepatitis B surface antigen (HBsAg) were identified at 5 HIV clinics. Testing for anti-hepatitis delta (HDV) antibodies, quantification of serum HIV RNA, HCV RNA, and HBV DNA, and determination of HBV and HCV genotype were performed. Out of 67 patients identified, 47 (70%) were receiving hepatitis B treatment.

Results


52.5% of the triply infected patients had detectable HCV RNA.


37.0% had detectable HBV DNA.


All possible serum marker patterns were found, regardless of anti-HBV therapy.


HDV infection was associated with undetectable HCV RNA (P = 0.007).


Independent factors predicting undetectable HBV DNA were lack of HBeAg (P = 0.00) and use of anti-HBV therapy (P = 0.002).


HBV or HCV genotypes and replication had no impact on the replication of the other virus.

In conclusion, the study authors wrote, "In this cohort of triple infection (HBV/HCV/HIV), various viral patterns were identified."

"Spontaneous HCV clearance was frequent, and it was independently associated with HDV coinfection," they noted. "In the absence of [anti-]HBV therapy, HBV most often actively replicates."

Finally, they stated "HBV/HCV replication or genotypes were not related to the replication of the other virus."

These findings conflict with those of some other studies suggesting that active HBV replication is associated with inhibition of HCV, and vice versa.

Istituto Malattie Infettive, Sassari, Italy; Hospital Carlos III, Madrid, Spain; Hospital Virgen de la Macarena, Sevilla, Spain; Hospital de Especialidades, México City, Mexico; Wake Forest University Health Sciences, Winston Salem, North Carolina.

6/17/08

Reference

I Maida, MJ Rios, L Perez-Saleme, and others. Profile of Patients Triply Infected with HIV and the Hepatitis B and C Viruses in the HAART Era. AIDS Research and Human Retroviruses 24(5): 679-683. May 1, 2008.

Related Articles

S Sollima, I Caramma I, B Menzaghi, and others. Chronic coinfection with hepatitis B and hepatitis C viruses in an Italian population of HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes 44: 606-607. 2007.

L Martin-Carbonero, P Barreir, G Jimenez-Galan, and others. Spontaneous clearance of hepatitis C virus in HIV-infected patients with multiple chronic viral hepatitis. Journal of Viral Hepatitis 14: 392-395. 2007.

M Jain, R Joshi, N Attar, and others. Comparison of triple infection with HIV/HBV/HCV to HIV/HCV and HIV/HBV. 14th Conference on Retroviruses and Opportunistic Infections (CROI 2007). Los Angeles, CA. February 25-28, 2007. Abstract 933.

V Soriano, P Barreiro, L Martin-Carbonero, and others. Treatment of chronic hepatitis B or C in HIV-infected patients with dual viral hepatitis. Journal of Infectious Diseases 195: 1181-1183. 2007.

V Soriano, M Puoti, M Sulkowski, and others. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 21: 1073-1089. 2007.

M Nunez, B Ramos B, B Diaz-Pollan, and others. Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy. AIDS Research and Human Retroviruses 22: 842-848. 2006.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

FDA-approved Hepatitis C
Treatments

Pegasys + Copegus
PEG-Intron + Rebetol
Intron A + Rebetol
Roferon A + Ribavirin
-
Treatment Guidelines
-
Experimental Treatments

FDA-approved HIV and
AIDS Treatments

Protease Inhibitors PIs
non Nucleoside Reverse
  
Transcriptase Inhibitors nNRTIs
Nucleoside / Nucleotide Reverse
  
Transcriptase Inhibitors NRTIs

Fixed-dose Combinations

Entry / Fusion Inhibitors EIs
Integrase Inhibitors
-
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
-
Experimental Treatments